JPMorgan Chase & Co’s Protalix BioTherapeutics PLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $51.1K | Buy |
34,545
+32,950
| +2,066% | +$48.8K | ﹤0.01% | 5092 |
|
|
2025
Q1 | $4.08K | Hold |
1,595
| – | – | ﹤0.01% | 5587 |
|
|
2024
Q4 | $3K | Hold |
1,595
| – | – | ﹤0.01% | 5535 |
|
|
2024
Q3 | $1.63K | Hold |
1,595
| – | – | ﹤0.01% | 5582 |
|
|
2024
Q2 | $1.87K | Sell |
1,595
-30,923
| -95% | -$36.2K | ﹤0.01% | 5517 |
|
|
2024
Q1 | $41K | Sell |
32,518
-11,216
| -26% | -$14.1K | ﹤0.01% | 5037 |
|
|
2023
Q4 | $77.8K | Hold |
43,734
| – | – | ﹤0.01% | 4867 |
|
|
2023
Q3 | $72.6K | Sell |
43,734
-1,026
| -2% | -$1.7K | ﹤0.01% | 4777 |
|
|
2023
Q2 | $89.5K | Buy |
+44,760
| New | +$89.5K | ﹤0.01% | 4686 |
|
|
2022
Q3 | – | Sell |
-395
| Closed | – | – | 5749 |
|
|
2022
Q2 | $0 | Sell |
395
-732
| -65% | – | ﹤0.01% | 5827 |
|
|
2022
Q1 | $1K | Buy |
+1,127
| New | +$1K | ﹤0.01% | 5654 |
|
|
2021
Q4 | – | Sell |
-5,847
| Closed | -$8K | – | 5857 |
|
|
2021
Q3 | $8K | Buy |
+5,847
| New | +$8K | ﹤0.01% | 5267 |
|
|
2021
Q2 | – | Sell |
-1,293
| Closed | -$6K | – | 5610 |
|
|
2021
Q1 | $6K | Sell |
1,293
-807
| -38% | -$3.75K | ﹤0.01% | 5074 |
|
|
2020
Q4 | $8K | Hold |
2,100
| – | – | ﹤0.01% | 4685 |
|
|
2020
Q3 | $8K | Buy |
2,100
+2,000
| +2,000% | +$7.62K | ﹤0.01% | 4624 |
|
|
2020
Q2 | $0 | Buy |
+100
| New | – | ﹤0.01% | 4892 |
|
|
2020
Q1 | – | Sell |
-100
| Closed | – | – | 4792 |
|
|
2019
Q4 | $0 | Hold |
100
| – | – | ﹤0.01% | 4834 |
|
|
2019
Q3 | $0 | Hold |
100
| – | – | ﹤0.01% | 4875 |
|
|
2019
Q2 | $0 | Hold |
100
| – | – | ﹤0.01% | 4904 |
|
|
2019
Q1 | $0 | Hold |
100
| – | – | ﹤0.01% | 4941 |
|
|
2018
Q4 | $0 | Buy |
+100
| New | – | ﹤0.01% | 4946 |
|